Kelly Huller - Mar 1, 2024 Form 4 Insider Report for GLOBUS MEDICAL INC (GMED)

Role
SVP, GC, Corporate Secretary
Signature
/s/ Kelly G. Huller
Stock symbol
GMED
Transactions as of
Mar 1, 2024
Transactions value $
-$218,980
Form type
4
Date filed
3/5/2024, 05:07 PM
Previous filing
Jan 30, 2024
Next filing
Oct 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GMED Class A Common Stock Options Exercise $187K +7.5K $24.90 7.5K Mar 1, 2024 Direct
transaction GMED Class A Common Stock Sale -$236K -4.39K -58.47% $53.79 3.12K Mar 1, 2024 Direct F1, F2
transaction GMED Class A Common Stock Sale -$170K -3.12K -100% $54.53 0 Mar 1, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GMED Stock Option (Right to Buy Class A Common Stock) Options Exercise $0 -7.5K -100% $0.00* 0 Mar 1, 2024 Class A Common Stock 7.5K $24.90 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan dated September 7, 2023 executed by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at a price range of $53.36 - $54.31, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the range set forth in footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at a price range of $54.43 - $54.64, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the range set forth in footnote (3) to this Form 4.
F4 These options were granted on March 4, 2014 and are fully vested.